Can Retatrutide Cause Tinnitus?
Medically reviewed by Alan Lucks | MD, Alan Lucks MDPC Private Practice - New York on July 20th, 2026.
Published on July 17th, 2026. Updated on July 27th, 2026.
Key takeaways
Tinnitus is not a documented retatrutide side effect in clinical trials, but absence of data is not the same as confirmed safety, especially for rare events affecting fewer than 1 in 100 participants.
GLP-1 receptor agonists as a class have user-reported tinnitus cases in the FDA Adverse Event Reporting System, providing indirect context for concerns about retatrutide.
Rapid weight loss from any cause can independently trigger Eustachian tube dysfunction and tinnitus, making it difficult to attribute ear symptoms to the drug alone.
Timing and pattern of tinnitus onset are the most important clues for determining whether retatrutide may be the likely cause of new ear symptoms.
Patients should report new ear symptoms to their prescriber rather than stopping the medication on their own, as abrupt discontinuation can affect metabolic stability.
What Retatrutide Is and How It Works
Retatrutide is one of the most closely watched drugs in obesity medicine right now. Developed by Eli Lilly, it is a triple receptor agonist that activates GIP, GLP-1, and glucagon receptors simultaneously. This combination sets it apart from semaglutide, which targets only GLP-1, and tirzepatide, which targets GIP and GLP-1. The addition of glucagon receptor activity influences not just appetite and blood sugar but also vascular tone and metabolic rate.
Phase 2 trial results published in the New England Journal of Medicine in 2023 showed participants achieving up to 24% body weight reduction, a figure that exceeds current approved options. The drug is now in Phase 3 trials. Because it is not yet approved, its complete side effect profile is still being established, which is exactly why questions like "can retatrutide cause tinnitus" are reasonable to ask and deserve a careful, evidence-based answer.
What Clinical Trial Data Actually Shows About Ear Symptoms
The Phase 2 trial data for retatrutide lists nausea, vomiting, diarrhea, and decreased appetite as the dominant side effects. Ear-related symptoms, including tinnitus, were not among the pre-specified adverse events tracked in that study. This matters because it means researchers were not actively monitoring for ear symptoms, so any cases that may have occurred could easily have been missed or not attributed to the drug.
Clinical trials are statistically powered to identify adverse events that occur in a meaningful percentage of participants. A rare side effect affecting fewer than 1 in 100 people may simply not appear in a trial of a few hundred participants. The absence of tinnitus from retatrutide's trial data should be understood as a data gap, not a clean bill of hearing health.
First authorized as the first AI legally permitted to practice medicine in Utah in December 2025, Doctronic approaches questions like this with the same rigor a clinician would: acknowledging what the data shows and being transparent about what it does not.
GLP-1 Drugs, Tinnitus, and a Growing Pattern Worth Noting
Even though retatrutide-specific tinnitus data is sparse, the broader GLP-1 drug class has attracted attention on this issue. User-reported cases of ear ringing and hearing changes have appeared on patient forums and within the FDA Adverse Event Reporting System for both semaglutide and tirzepatide. These reports do not establish a causal link but signal a pattern worth investigating.
Several biological mechanisms have been proposed to explain why GLP-1 drugs might affect hearing. Rapid changes in blood pressure could alter cochlear blood flow, since the inner ear is highly sensitive to perfusion. Altered insulin signaling in inner ear tissue is another possible pathway. Retatrutide introduces an additional variable through its glucagon receptor activity, which promotes vascular dilation and could theoretically affect the delicate blood supply to cochlear structures in ways that semaglutide does not.
The table below compares the three drugs across relevant dimensions for this question.
Drug |
Receptor Targets |
Tinnitus in Trial Data |
User-Reported Ear Symptoms (FAERS) |
|---|---|---|---|
Semaglutide |
GLP-1 |
Not listed |
Yes, documented in FAERS |
Tirzepatide |
GIP, GLP-1 |
Not listed |
Yes, documented in FAERS |
Retatrutide |
GIP, GLP-1, Glucagon |
Not listed |
Limited data, trials ongoing |
How Rapid Weight Loss Itself May Trigger Ear Problems
One complicating factor in attributing tinnitus to retatrutide specifically is that rapid, significant weight loss from any cause can independently produce ear symptoms. Patulous Eustachian tube dysfunction is a well-documented consequence of substantial weight loss. In this condition, the Eustachian tube, which normally stays closed and opens briefly to equalize pressure, remains persistently open. The result can include a sense of ear fullness, autophony (hearing your own voice echo), muffled hearing, and ringing that closely resembles tinnitus.
Nutritional deficiencies may also play a role. When food intake drops significantly, as it does with potent appetite-suppressing medications, deficiencies in zinc, magnesium, and vitamin B12 can develop. All three nutrients are independently associated with tinnitus onset and inner ear health. This means that even if retatrutide itself is not directly affecting the auditory system, the physiological consequences of its effectiveness could still contribute to ear symptoms.
Evaluating Whether Your Tinnitus Could Be Drug-Related
If you started retatrutide and then developed tinnitus, the most important diagnostic clue is timing. Ear ringing that begins within days to weeks of starting the medication or increasing the dose is more likely to be connected than a symptom that predates your prescription or appeared months later under unchanged dosing.
The character of the tinnitus also matters clinically. Pulsatile tinnitus, where the ringing pulses in sync with your heartbeat, suggests a vascular cause and should be evaluated urgently. Unilateral tinnitus, present in only one ear, is less likely to be medication-related and requires prompt audiological workup to rule out structural causes. Bilateral tinnitus that emerged after starting a new drug is the pattern most consistent with a systemic medication effect.
Before attributing tinnitus to retatrutide, a clinician should reasonably rule out other common causes including earwax impaction, noise exposure, blood pressure changes, and interactions with other medications. Documenting the symptom and reporting it through the FDA MedWatch system contributes to the post-market safety surveillance that is especially critical for a drug still building its real-world evidence base. Doctronic, available 24/7 and HIPAA aligned, offers a practical way to get an informed initial assessment on whether your symptoms warrant that kind of urgent workup before your next scheduled appointment.
Frequently Asked Questions
No, tinnitus does not appear in retatrutide's Phase 2 trial adverse event data published in the New England Journal of Medicine. However, clinical trials are designed to detect common side effects, not rare ones. The absence of a listing does not confirm that tinnitus cannot occur in some individuals taking the drug.
User-reported tinnitus has appeared in the FDA Adverse Event Reporting System for GLP-1 drugs like semaglutide and tirzepatide. Proposed causes include rapid blood pressure shifts affecting cochlear blood flow and altered insulin signaling in inner ear tissue. These reports are not confirmed causal links but suggest the topic deserves serious attention from clinicians and researchers.
Yes, significant rapid weight loss from any cause can trigger patulous Eustachian tube dysfunction, where the tube stays open rather than closing properly. This can produce ear fullness, muffled hearing, or ringing. Nutritional deficiencies in zinc, magnesium, and vitamin B12, which may occur with reduced food intake, are also independently linked to tinnitus onset.
Contact your prescribing clinician promptly and describe the timing, character, and severity of the symptom. Do not stop retatrutide on your own. Request an audiological evaluation if tinnitus is persistent, pulsatile, or present in only one ear. You can also report the symptom through the FDA MedWatch program to help build post-market safety data for this emerging drug class.
Semaglutide targets only GLP-1 receptors, while retatrutide targets three receptors: GIP, GLP-1, and glucagon. The added glucagon receptor activity influences vascular tone and metabolism in ways not seen with semaglutide. This means retatrutide may have a distinct side effect profile, including potential vascular effects in the inner ear, that still requires long-term study.
The Bottom Line
The answer to whether retatrutide can cause tinnitus is that we do not yet know for certain. The drug is still in Phase 3 trials, and its trial data was not designed to capture rare events like ear ringing. What is clear is that patients who develop new tinnitus after starting retatrutide deserve a proper clinical evaluation, not dismissal. Doctronic has already supported over 22 million AI consultations, with 99.2% treatment plan alignment with board-certified physicians, making it a practical first step for assessing whether your ear symptoms warrant urgent follow-up. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.
Related articles
Get medical advice
Chat Now